Effect of Intestinal Levodopa-Carbidopa Infusion on Pharyngeal Dysphagia: Results from a Retrospective Pilot Study in Patients with Parkinson’s Disease

Table 1

Descriptive statistics for the total cohort as well as for the subgroup with follow-up FEES examinations before and after beginning with levodopa-carbidopa intestinal gel (LCIG).

Gender men, n (%)
Total cohort	32 (71.1)
Subgroup	8 (72.7)
Mean age, ± SD
Total cohort	73.3 ± 8.2
Subgroup	74.6 ± 4.4
Mean time of disease in years ± SD
Total cohort	16.0 ± 6.5
Subgroup	15.2 ± 6.6
Mean time of LCIG in month ± SD
Total cohort	27.0 ± 22.3
Subgroup	28.4 ± 18.8
Dysphagia in FEES, n (%)
Total cohort	28 (62.2)
Subgroup	11 (100.0)
Dietary supplement, n (%)
Total cohort	9 (20.0)
Subgroup	2 (18.2)
Infections, n (%)
Total cohort	11 (24.4)
Subgroup	2 (18.2)
Pneumonia, n (%)
Total cohort	5 (11.1)
Subgroup	1 (9.1)
Discontinuation LCIG, n (%)
Total cohort	3 (6.7)
Subgroup	1 (9.1)
Complication total LCIG, n (%)
Total cohort	18 (40.0)
Subgroup	4 (36.4)
Dislocation LCIG, n (%)
Total cohort	16 (35.6)
Subgroup	3 (27.3)
Death, n (%)
Total cohort	3 (6.7)
Subgroup	1 (9.1)
Dementia, n (%)
Total cohort	22 (48.9)
Subgroup	7 (63.6)